Glimepiride/Dapagliflozin Propanediol Monohydrate

Tier C — Watch / trade

Jinyang Pharmaceutical Co Ltd

Originator

2023

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：SUR, KATP channels, SGLT2

Brand：DAPAGREEN-G

Indications (approved)：Type 2 diabetes

Regional status

China

Japan

Factories producing this API10

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

10 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Glimepiride/Dapagliflozin Propanediol Monohydrate?

Approved indications include: Type 2 diabetes.

When does the Glimepiride/Dapagliflozin Propanediol Monohydrate patent expire?

No public expiry year is available for Glimepiride/Dapagliflozin Propanediol Monohydrate yet; this page updates once verified.

How do I get a quote for Glimepiride/Dapagliflozin Propanediol Monohydrate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27